Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit Choroidal Neovascularization.

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Biology

Background:

• Exudative age-related macular degeneration (AMD) causes irreversible blindness due to choroidal neovascularization (CNV).
• Current anti-vascular endothelial growth factor (VEGF) treatments for AMD have limitations.
• Cell therapy offers a promising alternative for treating retinal degeneration and AMD.

Purpose of the Study:

• To investigate the efficacy of human umbilical tissue-derived cells (hUTCs) in inhibiting CNV.
• To determine the mechanism by which hUTCs affect VEGF production in retinal pigment epithelial (RPE) cells.

Main Methods:

• Subretinal injection of hUTCs in a rat model of laser-induced CNV.
• Co-culture of hUTCs with the human RPE cell line ARPE-19.
• Analysis of VEGF levels and identification of factors in hUTC conditioned medium (CM).

Main Results:

• Subretinal hUTC injection significantly inhibited CNV and reduced choroidal VEGF in vivo.
• VEGF release from ARPE-19 cells decreased when co-cultured with hUTCs.
• Soluble VEGF receptor 1 (sVEGFR1) secreted by hUTCs was identified as the factor inhibiting VEGF.

Conclusions:

• hUTCs inhibit angiogenesis by secreting sVEGFR1, which binds to VEGF.
• hUTCs represent a potential novel cell therapy for angiogenic ocular diseases like AMD.
• Further research into hUTCs could lead to new treatments for vision-threatening conditions.